Physician profile
Shivam Patel
NPI 1619554920
$475.18
in general payments reported to CMS, 2019-2025
14 companies · $297 in 2025
The $297 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $178 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $475.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $126.00 | 2024 | Dupixent |
| Boston Scientific Corporation | $49.92 | 2025 | Wavewriter Alpha Prime 16 |
| Astrazeneca Pharmaceuticals LP | $46.69 | 2024-2025 | Airsupra, Farxiga |
| Exact Sciences Corporation | $38.98 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abiomed | $38.84 | 2025 | |
| Lilly USA, LLC | $30.89 | 2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $23.22 | 2025 | Wegovy |
| Insulet Corporation | $18.90 | 2025 | Omnipod |
| Endo USA, INC. | $18.84 | 2024 | Aveed |
| Amgen INC. | $18.80 | 2025 | Repatha |
| Sumitomo Pharma America, INC. | $17.91 | 2024 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $16.23 | 2025 | |
| Dexcom, INC. | $15.71 | 2025 | Dexcom G6 Transmitter |
| Octapharma USA, INC. | $14.25 | 2025 | Fibryga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shivam Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.